BofA raised the firm’s price target on Amgen to $330 from $325 and keeps a Neutral rating on the shares. Amgen reported inline Q2 results and adjusted 2024 guidance modestly, raising the lower end of revenue guidance by $300M and narrowing the EPS range, the analyst noted. Overall, BofA would characterize the quarter as “uneventful as investors were unable to get more color on MariTide differentiation or results from the Uplizna phase 3 study in myasthenia gravis,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- AMGN Earnings: Amgen Stock Down on Mixed Q2 Results
- AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
- Options Volatility and Implied Earnings Moves Today, August 06, 2024
- Amgen granted orphan status for pancreatic cancer treatment
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024
Questions or Comments about the article? Write to editor@tipranks.com